LLY vs MNKD: fair value comparison
Eli Lilly and Company and MannKind Corporation · Updated 2026-08-31
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LLY currently sits closer to the top of our discount ranking. MNKD carries the stronger quality grade.
| LLY | MNKD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $1,174.61 | $3.80 |
| 12-month range | $735.19–$1,148.84 | $2.54–$6.01 |
| Sector rank | #12 of 113 Healthcare | #17 of 113 Healthcare |
| Quality grade | D | A |
| Momentum grade | B | — |
| Leverage | High | Low |
| Margin trend | Expanding | Expanding |
| Revenue growth | High | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | — | Mixed |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: LLY fair value analysis · MNKD fair value analysis